Chemistry:Moxaverine
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C20H21NO2 |
| Molar mass | 307.393 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Moxaverine has been used in therapy based on the direct vasodilatory effect of the drug, a phosphodiesterase inhibitor,[1] and on its influence on the rheological properties of red blood cells.[2]
Moxaverine hydrochloride (Kollateral forte®, Ursapharm. Saarbrücken, Germany) has been shown to increase ocular blood flow in patients with age-related macular degeneration, primary open angle glaucoma, and to increase choroidal and retrobulbar blood flow in elderly patients with eye diseases associated with hypo-perfusion.[3] The ocular efficacy of moxaverine has been explored in the clinic.[4]
References
- ↑ "Inhibition of calmodulin dependent c-AMP-phosphodiesterase by moxaverine and papaverine". Arzneimittel-Forschung 38 (12): 1806–8. December 1988. PMID 2854468.
- ↑ "Influence of moxaverine hydrochloride on membrane curvature and microsieve filterability of red cells after exposure to hyperosmolarity and lactacidosis". Arzneimittel-Forschung 38 (5): 710–6. May 1988. PMID 3415714.
- ↑ "The effects of moxaverine on ocular blood flow in patients with age-related macular degeneration or primary open angle glaucoma and in healthy control subjects". Acta Ophthalmologica 90 (2): 139–45. March 2012. doi:10.1111/j.1755-3768.2010.01878.x. PMID 20456253.
- ↑ Clinical trial number NCT01629680 for "A Randomized, Placebo-controlled Study Investigating the Effects of Moxaverine on Ocular Blood Flow After Oral Administration in Healthy Subjects" at ClinicalTrials.gov
 |  |
